Symbols

ICCM

IceCure Medical·NASDAQ

--(--)

ICCM fundamentals

ICCM Q4 2025 Earnings

IceCure Medical (ICCM) released its earnings on Mar 17, 2026: revenue was 1.30M (YoY +48.57%), met estimates; EPS was -0.05 (YoY +36.31%), met estimates.

Revenue / YoY

1.30M

+48.57%

EPS / YoY

-0.05

+36.31%

Report date

Mar 17, 2026

ICCM Earnings Call Summary for Q4,2025

Revenue Milestone: Full-year 2025 revenue of $3.4 million, driven by U.S. FDA clearance and ASBrS recommendation.
Market Validation: ProSense is the only FDA-cleared breast cancer device, with ASBrS endorsement accelerating adoption.
Growth Catalysts: 30 PMS sites identified, CPT 1 reimbursement expected 2028, and international expansion in Canada and Japan.
Operational Scale: U.S. sales team to triple by end-2026, targeting 3-9 month sales cycle conversion.

Earnings

EPS

Revenue

Revenue & Expenses

ICCM has released its 2025 Q4 earnings report, with revenue of 1.28M, reflecting a YoY change of 46.17%, and net profit of -4.25M, showing a YoY change of 5.20%. The Sankey diagram below clearly presents ICCM's revenue sources and cost distribution.

Key Indicators

IceCure Medical (ICCM) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

IceCure Medical (ICCM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

IceCure Medical (ICCM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

IceCure Medical (ICCM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown